Skip to content

Study to verify the efficacy of the intestinal regulating effect of the intake of seabuckthorn Juice.

Study to verify the efficacy of the intestinal regulating effect of the intake of seabuckthorn Juice. - Study to verify the efficacy of the intestinal regulating effect of the intake of seabuckthorn Juice.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055660
Enrollment
40
Registered
2024-10-01
Start date
2024-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Sponsors

Finess Co, Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Men and women between the ages of 20 and 64 (2) Those who tend to be constipated, with a normal frequency of bowel movements of about 3 to 5 times per week. (3) Those who have a regular diet (3 meals a day (breakfast, lunch, and dinner)) (4) Have given written consent to participate in the study voluntarily.

Exclusion criteria

Exclusion criteria: (1) Those with a confirmed diagnosis of constipation and chronic constipation or those who meet the criteria of the Guidelines for the Treatment of Chronic Constipation 2017. (2) Persons who consume foods or health foods listed as containing seabuckthorn Juice, the food under study. (3) Persons who regularly use medicines, health foods, foods for specified health uses, foods with functional claims (non-digestible dextrin, chitosan, oligosaccharides, etc.) that may affect bowel movements (4) Persons who are determined to be lactose intolerant, including self-reported lactose intolerance (5) Persons who habitually consume dietary supplements or dietary supplements related to immune function (6) Patients who are visiting the hospital or using drugs or over-the-counter laxatives for bowel movement-related diseases at the time of participation in the study (7) Have a disease or pre-existing condition that is considered to significantly affect bowel movements, such as irritable bowel disease or ulcerative colitis. (8) Those who work night shifts or day/night shifts (9) Patients who are undergoing treatment at a medical institution for treatment or prevention of disease, or whose condition is judged to be in need of treatment at the time of obtaining consent. (10) Those with a history of serious diseases of the glucose metabolism, lipid metabolism, liver function, renal function, heart, circulatory system, respiratory system, endocrine system, immune system, or nervous system, or psychiatric diseases (11) Those with a history of alcohol and drug dependence (12) Persons who are at risk of developing allergies to foods (13) Pregnant or lactating at the time consent is obtained, or wishes to become pregnant during the study period (14)Persons who are deemed by the investigator (or the study investigator) to be unsuitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
Number of days of defecation, frequency of defecation

Secondary

MeasureTime frame
Defecation volume, distribution of intestinal flora (bacterial flora), shape of defecation, stool color, odor, sensation after defecation

Countries

Japan

Contacts

Public ContactShigenori Nibun

EAS inc. Clinical Trial Session

info@eas-ct.jp045-374-3392

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026